FDA approves PureTech’s KarXT to treat schizophrenia in adults
WEB1 day ago · The financial implications of the FDA approval are substantial for PureTech. The company is set to receive approximately 2% in royalties on net annual sales exceeding $2bn. Cobenfy’s success, including the proceeds from BMS’ acquisition of Karuna and an agreement with Royalty Pharma, has generated roughly $1.1bn for PureTech to date.
PureTech-Invented KarXT Receives U.S. Food and Drug …
WEB4 days ago · PureTech’s business model is designed to repeat and scale this type of outcome, and proceeds from the success of Cobenfy have enabled PureTech to self-fund the advancement of several programs ...
PureTech-Invented KarXT Receives U.S. Food and Drug …
WEB5 days ago · PureTech's business model is designed to repeat and scale this type of outcome, and proceeds from the success of Cobenfy have enabled PureTech to self-fund the advancement of several programs - including LYT-100 (deupirfenidone), LYT-200 (anti-galectin-9 mAb), and the Glyph TM platform supporting the pipeline of …
PureTech-Invented KarXT Receives U.S. Food and Drug ... - BioSpace
WEB5 days ago · PureTech’s business model is designed to repeat and scale this type of outcome, and proceeds from the success of Cobenfy have enabled PureTech to self-fund the advancement of several programs – including LYT-100 (deupirfenidone), LYT-200 (anti-galectin-9 mAb), and the Glyph TM platform supporting the pipeline of …
PureTech News
WEBPureTech Founded Entity Vor Bio Announces New Clinical Data Validating Approach of Using Shielded Transplants to Deliver Targeted Therapies. Continue.
Puretech Health - News & Press
WEBPress releases. 2024-09-06. PureTech Founded Entity Vor Bio Announces New Clinical Data Validating Approach of Using Shielded Transplants to Deliver Targeted Therapies. Continue.
Bristol Myers Squibb Completes Acquisition of PureTech's …
WEBMar 18, 2024 · PureTech's R&D engine has resulted in the development of 28 therapeutics and therapeutic candidates, including two that have received both US FDA clearance and European marketing authorization...
PureTech Year End Update and Outlook for 2024
WEBDec 20, 2023 · Rapid growth of neuroscience pipeline, powered by Glyph platform, including new therapeutic candidate announced today (LYT-320), and initiations of two clinical trials in 2024 (LYT-300 and LYT-310).
2024-09-27 | PureTech-Invented KarXT Receives U.S. Food
WEB5 days ago · PureTech’s business model is designed to repeat and scale this type of outcome, and proceeds from the success of Cobenfy have enabled PureTech to self-fund the advancement of several programs – including LYT-100 (deupirfenidone), LYT-200 (anti-galectin-9 mAb), and the Glyph TM platform supporting the pipeline of Seaport ...
PureTech-Invented KarXT Receives U.S. Food and Drug …
WEB5 days ago · PureTech’s monetization of equity holdings in Karuna, including gross proceeds from the BMS acquisition of Karuna, and a strategic royalty agreement with Royalty Pharma have enabled PureTech to ...